Related Experiment Video
Updated: Jul 5, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Current antiviral therapies for chronic hepatitis B
1Department of Medicine and Clinical Oncology, Postgraduate School of Medicine, Chiba University, Chiba, Japan.
Summary
Nucleoside/nucleotide analogs offer better tolerability for chronic hepatitis B treatment than interferon (IFN). However, drug resistance is a key challenge with these analogs, requiring careful patient management and ongoing research.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis B treatment involves interferon (IFN) and nucleoside/nucleotide analogs.
- IFN therapy has severe side effects and low response rates.
- Nucleoside/nucleotide analogs offer better tolerability but face challenges with drug resistance and sustained response.
Purpose of the Study:
- To review current nucleoside/nucleotide analog therapies for chronic hepatitis B.
- To discuss the efficacy and limitations of existing treatments like lamivudine, adefovir, and entecavir.
- To highlight emerging nucleoside/nucleotide analog treatments.
Main Methods:
- Literature review of current treatment options for chronic hepatitis B.
- Analysis of clinical data on nucleoside/nucleotide analog efficacy and resistance.
- Comparison of different analog therapies and their application in treatment-naïve and resistant patients.
Main Results:
- Nucleoside/nucleotide analogs are generally well-tolerated with high response rates.
- Lamivudine resistance is a significant issue, with adefovir showing efficacy in such cases.
- Adding adefovir to lamivudine may be superior to switching for viral suppression and resistance prevention.
- Entecavir is a potential first-line option for treatment-naïve patients, but cross-resistance requires consideration.
Conclusions:
- Nucleoside/nucleotide analogs represent a significant advancement in chronic hepatitis B management.
- Careful selection of therapy, considering resistance patterns, is crucial for optimal patient outcomes.
- Ongoing development of new analogs like telbivudine, clevudine, and tenofovir promises further treatment improvements.
Related Concept Videos
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...